tbuckley/cabot-search huggingface dataset:
Association of <i>APOA5</i> and <i>APOC3</i> Genetic Polymorphisms With Severity of Hypertriglyceridemia in Patients With Cutaneous T-Cell Lymphoma Treated With Bexarotene
Authors: Irene Cabello, Pedro Alia, Xavier Pintó, Cristina Muniesa, Ricardo Fernandez-de-Misa, Yerai Peñate, Mercedes Morillo, Amparo Perez-Farriols, Teresa Estrach, Rosa Izu, Fernando Gallardo, Concepción Román, Iván Cervigón, Ariadna Ortiz-Brugues, Pablo L. Ortiz-Romero, Octavio Servitje
Journal: JAMA Dermatology (2018)

<h3>Importance</h3> Hypertriglyceridemia is the most frequent and limiting adverse effect of bexarotene therapy in cutaneous T-cell lymphoma (CTCL). Despite standard prophylactic measures, there is a wide variability in the severity of this complication, which could be associated with both genetic and environmental factors. <h3>Objectives</h3> To analyze the association between genetic polymorphisms of apolipoprotein genes<i>APOA5</i>,<i>APOC3</i>, and<i>APOE</i>and the severity of hypertriglyceridemia during bexarotene therapy and to optimize patient selection for bexarotene therapy based on adverse effect profile. <h3>Design, Setting, and Participants</h3> This case series study was conducted in 12 university referral hospitals in Spain from September 17, 2014, to February 6, 2015. One hundred twenty-five patients with a confirmed diagnosis of CTCL who had received bexarotene therapy for at least 3 months were enrolled. Nine patients were excluded owing to missing analytic triglyceride level data, leaving a study group of 116 patients. Data on demographic and cardiovascular risk factor were collected, and a complete blood analysis, including lipid profile and genetic analysis from a saliva sample, was performed. <h3>Main Outcomes and Measures</h3> Primary outcomes were the maximal triglyceride levels reported in association with the minor alleles of the polymorphisms studied. <h3>Results</h3> Among 116 patients, the mean (SD) age was 61.2 (14.7) years, 69 (59.5%) were men, and 85 (73.2%) had mycosis fungoides, the most prevalent form of CTCL. During bexarotene therapy, 96 patients (82.7%) experienced hypertriglyceridemia, which was severe or extreme in 8 of these patients (8.3%). Patients who carried minor alleles of the polymorphisms did not show significant differences in baseline triglyceride concentrations. After bexarotene treatment, carriers of at least 1 of the 2 minor alleles of<i>APOA5</i>c.-1131T&gt;C and<i>APOC3</i>c.*40C&gt;G showed lower levels of triglycerides than noncarriers (mean [SD], 241.59 [169.91] vs 330.97 [169.03] mg/dL, respectively;<i>P</i> = .02). <h3>Conclusions and Relevance</h3> These results indicate that the screening of<i>APOA5</i>and<i>APOC3</i>genotypes may be useful to estimate changes in triglyceride concentrations during bexarotene treatment in patients with CTCL and also to identify the best candidates for bexarotene therapy based on the expected adverse effect profile.
Impact of a molecular prescreening program (MPP) in the management of patients with non-glioblastoma brain tumors
Authors: J.C. Benítez Montañez, M. Vieito Villar, C. Hierro, M. Gonzalez Rodriguez, I. Matos, I. Braña Garcia, C. Suarez Rodriguez, E.A. Martinez Saez, M.C. Perez-Gago, R. Morales-Barrera, C. Ortiz, C. Suarez, X. Maldonado, F. Martinez-Ricarte, C. Auger, A. Azaro, R. Dienstmann, J. Carles, E. Garralda
Journal: Annals of Oncology (2018)
P2.13-09 Efficacy and Safety of Osimertinib After Prior EGFR TKI: Analysis of Patients Underrepresented in Randomized Clinical Trials
Authors: L.H. Araujo, G. Castro, P. De Marchi, C. Baldotto, G. Werutsky, G. Borges, C. Mathias, A. Calabrich, C. Costa, F. Franke, E. Lima, Y. Neron, G. Schwartsmann, M. Custodio, C. Sansevero, H. Freitas
Journal: Journal of Thoracic Oncology (2018)
Clinical prognostic factors in patients (pts) with recurrent and/or metastatic (RM) head and neck carcinoma (HNC) treated with cetuximab plus chemotherapy
Authors: P. Bossi, R. Depenni, M. cossu rocca, D. Ferrari, G. Azzarello, M. Alù, F. Nolè, C. Codecà, G. Boscolo, M. Piccininni, S. Cavalieri, G. Pugliese, L.F. Licitra
Journal: Annals of Oncology (2018)
Genetic disease risks can be misestimated across global populations
Authors: Michelle S. Kim, Kane P. Patel, Andrew K. Teng, Ali J. Berens, Joseph Lachance
Journal: Genome biology (2018)

Accurate assessment of health disparities requires unbiased knowledge of genetic risks in different populations. Unfortunately, most genome-wide association studies use genotyping arrays and European samples. Here, we integrate whole genome sequence data from global populations, results from thousands of genome-wide association studies (GWAS), and extensive computer simulations to identify how genetic disease risks can be misestimated.In contrast to null expectations, we find that risk allele frequencies at known disease loci are significantly different for African populations compared to other continents. Strikingly, ancestral risk alleles are found at 9.51% higher frequency in Africa, and derived risk alleles are found at 5.40% lower frequency in Africa. By simulating GWAS with different study populations, we find that non-African cohorts yield disease associations that have biased allele frequencies and that African cohorts yield disease associations that are relatively free of bias. We also find empirical evidence that genotyping arrays and SNP ascertainment bias contribute to continental differences in risk allele frequencies. Because of these causes, polygenic risk scores can be grossly misestimated for individuals of African descent. Importantly, continental differences in risk allele frequencies are only moderately reduced if GWAS use whole genome sequences and hundreds of thousands of cases and controls. Finally, comparisons between uncorrected and corrected genetic risk scores reveal the benefits of considering whether risk alleles are ancestral or derived.Our results imply that caution must be taken when extrapolating GWAS results from one population to predict disease risks in another population.
P1.01-81 Phase 3 Study of Pemetrexed-Platinum with or without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789
Authors: G. Riely, R. Hui, D. Carbone, K. Park, M. Carrigan, X. Xu, T. Dang, J. Chih-Hsin Yang
Journal: Journal of Thoracic Oncology (2018)
A biomarker study to validate predictors for clinical outcome of cetuximab based chemotherapy in first-line metastatic colorectal cancer (mCRC) patients: JACCRO CC-05/06AR and FIRE-3
Authors: Y. Sunakawa, S. Stintzing, S. Cao, J. Luecke, D. Thompson, M. Moran, S.H. Astrow, J. Hsiang, C. Stephens, W. Zhang, A. Tsuji, T. Takahashi, T. Denda, K. Shimada, M. Kochi, M. Takeuchi, M. Fujii, W. Ichikawa, V. Heinemann, H.-J. Lenz
Journal: Annals of Oncology (2018)
Preliminary safety, pharmacokinetics (PK) and efficacy results from a phase I study of CS1001, an anti-programmed death ligand-1 (PD-L1) monoclonal antibody (mAb) in patients (pts) with advanced tumors
Authors: L. Shen, J. Cao, J. Gong, D. Ji, Z. Qin, H. Dai, K. Wu, J. Xu, J. Yang
Journal: Annals of Oncology (2018)
P3.01-67 Integrated Network Analysis to Understand the Potential Mechanisms of Hydroxychlrorquine in Non-Small Cell Lung Cancer Treatment
Authors: X. Lyu, J. Chen, L. Zeng, J. Yuan, X. Meng, R. Sun, B. Liu, Y. Bai, X. Liu, Z. Li, S. Yang
Journal: Journal of Thoracic Oncology (2018)
Lumen-apposing metal stent acted as an interim role in walled-off necrosis drainage
Authors: Huiyun Zhu, Han Lin, Xiangyu Kong, Zhendong Jin, Zhaoshen Li, Yiqi Du
Journal: Gut (2018)

Recently, Bang et al 1 conducted the first randomised trial on lumen-apposing metal stents (LAMS) versus plastic stents for endoscopic ultrasonography (EUS)-guided drainage of walled-off necrosis (WON), which provided significant information for the clinical application of LAMS. We agree with Bang et al 1 that the wider diameter of LAMS facilitates more rapid drainage of necrotic contents leading to faster WON resolution, and we agree that LAMS must be removed at 3 weeks postprocedure if the WON resolved. Our endoscopy centre observed LAMS-related adverse events, including stent buried in tissue2 and cardia occlusion,3 at more than 3 weeks postprocedure.

Bang et al 1 stated that disconnected pancreatic duct …
P1.14-11 The Expression Pattern of Programmed Death-Ligand 1 According to the Pathological Type of Malignant Thymic Epithelial Tumors
Authors: S. Ishihara, S. Okada, H. Ogi, Y. Kodama, K. Itoh, A. Marx, M. Inoue
Journal: Journal of Thoracic Oncology (2018)
IMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC
Authors: M. Reck, T. Wehler, F. Orlandi, N. Nogami, C. Barone, D. Moro-Sibilot, M. Shtivelband, J.L. González Larriba, J. Rothenstein, M. Frueh, G. Shankar, A. Lee, Y. Deng, H. Patel, C. Kelsch, W. Lin, M.A. Socinski
Journal: Annals of Oncology (2018)
MA20.06 Lung Cancer Screening Pilot for People at High Risk: Early Results on Cancer Detection and Staging
Authors: G. Darling, H. Schmidt, M. Yu, M. Luettschwager, B. Pylypenko, T. Patel, V. Rivera, K. Pearson, K. Larson, M. Tammemagi
Journal: Journal of Thoracic Oncology (2018)
Cost-effectiveness (CE) of avelumab vs standard care (SC) for the treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC)
Authors: M. Bharmal, A. Amin, C. Stapelkamp, C. Pescott, A. Hatswell, C. Lilley, A. Bullement, A. Willis
Journal: Annals of Oncology (2018)
Health disparities across the counties of Kenya and implications for policy makers, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
Authors: Tom Achoki, Molly K Miller-Petrie, Scott D Glenn, Nikhila Kalra, Abaleng Lesego, Gladwell K Gathecha, Uzma Alam, Helen W Kiarie, Isabella Wanjiku Maina, Ifedayo M O Adetifa, Hellen C Barsosio, Tizta Tilahun Degfie, Peter Njenga Keiyoro, Daniel N Kiirithio, Yohannes Kinfu, Damaris K Kinyoki, James M Kisia, Varsha Sarah Krish, Abraham K Lagat, Meghan D Mooney, Wilkister Nyaora Moturi, Charles Richard James Newton, Josephine W Ngunjiri, Molly R Nixon, David O Soti, Steven Van De Vijver, Gerald Yonga, Simon I Hay, Christopher J L Murray, Mohsen Naghavi
Journal: The Lancet Global Health (2018)

BackgroundThe Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016 provided comprehensive estimates of health loss globally. Decision makers in Kenya can use GBD subnational data to target health interventions and address county-level variation in the burden of disease.MethodsWe used GBD 2016 estimates of life expectancy at birth, healthy life expectancy, all-cause and cause-specific mortality, years of life lost, years lived with disability, disability-adjusted life-years, and risk factors to analyse health by age and sex at the national and county levels in Kenya from 1990 to 2016.FindingsThe national all-cause mortality rate decreased from 850·3 (95% uncertainty interval [UI] 829·8–871·1) deaths per 100 000 in 1990 to 579·0 (562·1–596·0) deaths per 100 000 in 2016. Under-5 mortality declined from 95·4 (95% UI 90·1–101·3) deaths per 1000 livebirths in 1990 to 43·4 (36·9–51·2) deaths per 1000 livebirths in 2016, and maternal mortality fell from 315·7 (242·9–399·4) deaths per 100 000 in 1990 to 257·6 (195·1–335·3) deaths per 100 000 in 2016, with steeper declines after 2006 and heterogeneously across counties. Life expectancy at birth increased by 5·4 (95% UI 3·7–7·2) years, with higher gains in females than males in all but ten counties. Unsafe water, sanitation, and handwashing, unsafe sex, and malnutrition were the leading national risk factors in 2016.InterpretationHealth outcomes have improved in Kenya since 2006. The burden of communicable diseases decreased but continues to predominate the total disease burden in 2016, whereas the non-communicable disease burden increased. Health gains varied strikingly across counties, indicating targeted approaches for health policy are necessary.FundingBill & Melinda Gates Foundation.
Irinotecan, oxaliplatin, 5-fluorouracil/leucovorin (FOLFIRINOX) as first-line therapy in advanced HER2-negative gastric or gastroesophageal adenocarcinoma (G/GEA)
Authors: E. Obarevich, N. Besova, E. Trusilova, V. Gorbunova
Journal: Annals of Oncology (2018)
Abstract 20242: Routine DFT Testing in Patients Undergoing ICD Implantation Does Not Improve Mortality: A Systematic Review & Meta-Analysis
Authors: Munish Kannabhiran, Madan Acharya, Nelson Telles, Alexandria Brackett, Pratap Reddy, Paari Dominic
Journal: Circulation (2016)

Introduction: Traditionally, Defibrillation threshold (DFT) testing has been an integral part of implantable cardioverter-defibrillator (ICD) implantation to confirm appropriate sensing of ventricu...
Intra-CSF liposomal cytarabine plus systemic therapy as initial treatment of breast cancer leptomeningeal metastasis: A randomised, open-label trial
Authors: E. Le Rhun, A. Mailliez, J. Wallet, I. Rodrigues, T. Boulanger, I. Desmoulins, J. Barriere, M. Fabbro, S. Taillibert, C. Andre, M.C. Le Deley, M. Weller, J.M. Bonneterre
Journal: Annals of Oncology (2018)
P3.01-43 Predictive Value of Computed Tomography Characteristics for Nivolumab Response in Pretreated Non-Small Cell Lung Cancer
Authors: H. Imai, H. Minemura, H. Moriya, T. Sugiyama, Y. Yamada, M. Higuchi, K. Kaira, Y. Ozaki, K. Kanazawa, H. Yokouchi, T. Kasai, T. Kaburagi, H. Suzuki, K. Minato, Y. Shibata
Journal: Journal of Thoracic Oncology (2018)
Retrospective analysis of the treatment of metastatic uveal melanoma comparing systemic chemotherapy and transarterial chemoembolization
Authors: C.A. Peuker, L. Polzin, S. Ochsenreither, M. De Bucourt, S. Leyvraz, U. Keilholz, A. Joussen, J. Eucker
Journal: Annals of Oncology (2018)
Abstract 18377: Prospective, Multi-center Trial to Determine the Effect of Viewing a 60-second Video on Emergency Department Patients and Their Companions Willingness to Perform Compression-only Cardiopulmonary Resuscitation
Authors: Tanya Dall, Valerie Tainsh, David Carlberg, Olga E Garcia, Jaime Konieczny, Munish Goyal
Journal: Circulation (2015)

Introduction: Bystander CPR is uncommonly performed in out-of-hospital cardiac arrest patients transported to our ED. Previous studies suggest adults without formal CPR training can retain compression-only CPR skills with a single viewing of a 60 second, AHA training video. We sought to determine the impact of viewing this video on the willingness of ED patients and their companions to perform compression-only CPR. Hypothesis: Watching a 60 second AHA CPR training video is associated with a 10% increase in willingness to perform CPR. Methods: A convenience sample of adults age 18-70 from two urban, academic EDs with socioeconomically diverse patient populations was recruited. Patients in hallways and non-english speakers were excluded. Subjects were asked to complete a pre-video survey to assess baseline knowledge and willingness to perform CPR on a stranger and on family/friends, watch a 60 second, previously validated AHA CPR instructional video, and then complete a post-training CPR survey. Willingness was scored as 1 (not at all likely) to 5 (extremely likely). An answer of 4 or 5 was considered “willing to perform CPR”. A sample size of 110 subjects from each hospital was determined necessary to detect at 10% absolute difference assuming 0.80 power and one-sided alpha level of 0.05. Sign and McNemar's tests were used to compare pre and post video measurements. Results: Between 1/1/15 to 6/7/15, 281 patients and their companions were approached about study participation, of which 229 (82%) consented; complete data were available for 216 subjects. Subjects were mean age 47, 66% female, 68% black, and 69% college educated. After watching the video, willingness to perform CPR on a stranger increased by 29%, from 57% to 86% (p&lt; 0.001). Willingness to perform CPR on family/friends increased by 19%, from 75% to 94% (p&lt;0.001). Among subjects whose willingness to perform CPR changed (110 on a stranger and 67 on family/friends, respectively), 98% (108) and 96% (64) changed from less willing to more willing. Conclusion: In adult patients and their companions in two diverse, academic EDs, watching a 60 second CPR training video was associated with a significant absolute increase in willingness to perform compression-only CPR on a stranger (29%) and on family/friends (19%).
OA02.06 A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)
Authors: J. Heymach, M. Negrao, J. Robichaux, B. Carter, A. Patel, M. Altan, D. Gibbons, F. Fossella, G. Simon, V. Lam, G. Blumenschein, A. Tsao, J. Kurie, F. Mott, D. Jenkins, D. Mack, L. Feng, B. Roeck, Z. Yang, V. Papadimitrakopoulou, Y. Elamin
Journal: Journal of Thoracic Oncology (2018)
A multicenter single-arm phase II study of nab-paclitaxel/carboplatin for non-small cell lung cancer patients with interstitial lung disease
Authors: Y. Usui, H. Kenmotsu, K. Mori, A. Ono, K. Yoh, T. Baba, Y. Fujiwara, O. Yamaguchi, R. Ko, H. Okamoto, N. Yamamoto, T. Ninomiya, T. Ogura, T. Kato
Journal: Annals of Oncology (2018)
P1.01-45 Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey
Authors: S. Kılıçkap, A. Ozturk, N. Karadurmuş, T. Korkmaz, P. Yumuk, İ. Çiçin, S. Paydaş, E. Çılbır, T. Sakalar, M. Uysal, N. Üskent, N. Demir, A. Sakin, N. Turhal, S. Keskin, D. Tural, Y. Eralp, F. Basal, H. Yaşar, M.A. Sendur, U. Demirci, E. Çubukçu, M. Karaağaç, Ş. Karaca, A. Tatlı, T. Yetisyigit, S. Urvay, P. Gürsoy, B. Oyan Uluç, Z. Turna, M. Kucukoner, Ö. Ölmez, D. Çabuk, M. Şeker, O. Ünal, N. Meydan, S. Okutur, D. Tunalı
Journal: Journal of Thoracic Oncology (2018)
ARCTIC: Durvalumab + tremelimumab and durvalumab monotherapy vs SoC in ≥ 3L advanced NSCLC treatment
Authors: D.M. Kowalski, N. Reinmuth, S.V. Orlov, J.R. Fischer, S. Sugawara, S. Mandziuk, D.M. Medine, S. Novello, Y. Takeda, R.A. Soo, K. Park, M. McCleod, S.L. Geater, M. Powell, R. May, P. Stockman, D. Planchard
Journal: Annals of Oncology (2018)
P1.09-35 Clinical Impact of Systematic Inflammation and Histologic Grade in Non Small Cell Lung Carcinoma (NSCLC)
Authors: N. Tsoukalas, C. Giaginis, K. Tsapakidis, M. Tolia, I. Binas, E. Aravantinou, P. Baxevanos, M. Galanopoulos, M. Kiakou, I. Zerdes, I. Kostakis, C. Nikolaou, I. Litos, M. Liontos, E. Tsiambas, I. Gioulbasanis, A. Karameris, K. Liaskonis, G. Kyrgias, S. Theocharis
Journal: Journal of Thoracic Oncology (2018)
Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial
Authors: Sinead Delany-Moretlwe, Carl Lombard, Deborah Baron, Linda-Gail Bekker, Busi Nkala, Khatija Ahmed, Modulakgotla Sebe, William Brumskine, Maposhane Nchabeleng, Thesla Palanee-Philips, Julius Ntshangase, Sidney Sibiya, Emilee Smith, Ravindre Panchia, Landon Myer, Jill L Schwartz, Mark Marzinke, Lynn Morris, Elizabeth R Brown, Gustavo F Doncel, Glenda Gray, Helen Rees
Journal: The Lancet Infectious Diseases (2018)
The standard of care for stage III NSCLC in the era of immunotherapy: An Italian national survey on the current pattern of care among Italian thoracic oncologists
Authors: A. Bruni, F. Grossi, F. Katia, E. Capelletto, L. Buffoni, S. Badellino, V. Poletti, R. Chiari, N. Giaj Levra, G.L. Banna, S. Vagge, P. Borghetti, E. Baldini, E. Bria, M. Tiseo, M. Paci, P. Ciammella, M. Taraborrelli, U. Ricardi, V. Scotti
Journal: Annals of Oncology (2018)
TAGS: A phase III, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer
Authors: H.-T. Arkenau, J. Tabernero, K. Shitara, M. Dvorkin, W. Mansoor, A. Prokharau, M. Alsina, M. Ghidini, C. Faustino, V. Gorbunova, E.A. Zhavrid, K. Nishikawa, A. Hosokawa, D. Ganea, Ş Yalçın, G.D. Beretta, R.E. Winkler, L. Makris, T. Doi, D.H. Ilson
Journal: Annals of Oncology (2018)
MA16.09 Feasibility, Clinical Relevance of ALK/ROS1 Fusion Variant Detection by Liquid Biopsy in Advanced Non-Small Cell Lung Cancer
Authors: A. Swalduz, L. Mezquita, S. Ortiz-Cuaran, C. Jovelet, V. Avrillon, D. Planchard, S. Marteau, G. Recondo, S. Martinez, K. Howarth, V. Plagnol, C. Morris, E. Green, L. Odier, L. Lacroix, S. Hominal, E. Rouleau, C. Tissot, C. Caramella, P. Fournel, L. Friboulet, M. Pérol, B. Besse, P. Saintigny
Journal: Journal of Thoracic Oncology (2018)
P2.03-05 Biologic Profiling of Brain Metastasis from Non-Small Cell Lung Cancer
Authors: T. Saito, R. Iwata, M. Maruyama, Y. Nakano, K. Ofune, S. Matsuda, M. Kaibori, T. Murakawa, M. Hayashi
Journal: Journal of Thoracic Oncology (2018)
MA16.10 Clinical Utility of Cerebrospinal Fluid Cell-Free DNA for Clarifying Genetic Features of Leptomeningeal Metastases in ALK Rearrangement NSCLC
Authors: M. Zheng, Y. Li, B. Jiang, H. Tu, X. Zhang, J. Ye, W. Tang, S. Chuai, Y. Wu
Journal: Journal of Thoracic Oncology (2018)
Infographic. Physical activity for disabled adults
Authors: Brett Smith, Nathalie Kirby, Bethany Skinner, Leanne Wightman, Rebekah Lucas, Charlie Foster
Journal: British Journal of Sports Medicine (2018)

Despite the benefits of physical activity, in the UK many disabled adults live insufficiently active lifestyles. They are also more likely to be inactive when compared with non-disabled people. For example, recently it was reported that 43% of disabled people did less than 30 min per week of activity, while for non-disabled it was 21%.1 Given the health and economic implications of inactivity, promoting physical activity to disabled adults and reducing participation inequalities is a public health priority.

In 2011, the UK Chief Medical Officers’ (CMOs) physical activity guidelines were produced for four age groups, from under 5s to older adults. However, with sparse evidence on physical activity for those with disability available, the guidelines omitted guidance for this group. In 2018, Public Health England (PHE) tasked us to review the evidence and, if sufficient, co-produce evidence-based recommendations about physical activity and disability in an appropriate format.

The review established various benefits of physical activity for disabled adults, such as improved quality of life.2 Based on the evidence, it was recommended that disabled …
18F-FDG PET/CT of Internal Mammary Lymph Node Hepatocellular Carcinoma Metastases
Authors: Raja Senthil, H Ramesh, Arun Visakh R., Thara Pratap, Pushpa Mahadevan
Journal: Clinical Nuclear Medicine (2018)

Hepatocellular carcinoma usually metastasizes to regional abdominal lymph nodes. Distant lymph nodal metastases are relatively rare with most common extra abdominal sites being mediastinum and juxtaphrenic regions. Metastasis to internal mammary lymph nodes is extremely rare, and we present a case of hepatocellular carcinoma with histopathologically proven internal mammary lymph nodal metastasis in the absence of regional abdominal lymph nodal metastases.
Balixafortide (a novel CXCR4 inhibitor) and eribulin in HER2-neg metastatic breast cancer (MBC) patients (pts): A phase I trial
Authors: J. Cortes Castan, M. Martín, S. Pernas Simon, P. Gomez Pardo, S. Lopez-Tarruella, M. Gil Martin, L.M. Manso, E.M. Ciruelos, J.A. Perez Fidalgo, C. Hernando, F. Ademuyiwa, K. Weilbaecher, I.A. Mayer, T. Pluard, M. Martinez Garcia, L.T. Vahdat, A. Wach, D. Barker, B. Romagnoli, P.A. Kaufman
Journal: Annals of Oncology (2018)
MA03.09 Transcriptome-Wide Association Study Reveals Candidate Causal Genes for Lung Cancer
Authors: A. Clemenceau, M. Lamontagne, R. Carreras Torres, M. Obeidat, W. Timens, P. Joubert, C. Amos, J. Mckay, Y. Bossé
Journal: Journal of Thoracic Oncology (2018)
Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Authors: A. De Nonneville, C. Jauffret, A. Gonçalves, J.-M. Classe, M. Cohen, F. Reyal, C. Mazouni, M.-P. Chauvet, N. Chopin, P.-E. Colombo, E. Jouve, E. Darai, R. Rouzier, C. Coutant, P. Gimbergues, A.-S. Azuar, C. Tunon de Lara, E. Lambaudie, G. Houvenaeghel
Journal: Annals of Oncology (2018)